 Fennec Pharmaceuticals Inc. Nasdaq: FENC; TSX: FRX, a specialty pharmaceutical company, today announced that the companys Marketing Authorization Application MAA for its investigational drug, sodium thiosulfate unique formulation for infusion tradename to be determined in EU, has passed validation and is now under evaluation by the European Medicines Agency EMA. The MAA for Pediatric Use Marketing Authorization PUMA was filed in early February 2020 for the prevention of ototoxicity induced by cisplatin chemotherapy in patients one month to 18 years of age with localized, non-metastatic, solid tumors. 